With 2020 slowly drawing to an end after being one of the most difficult years in recent history, we have an uplifting and positive health story to report.
Over the last few months, we’ve been quietly working behind the scenes with Genomics England, beginning the process of promoting their latest work and role in the future of personalised medicine.
We appreciate getting your head around a topic like genetics can be a challenge. But ,both what they’ve done to date and their plans for the future are genuinely fascinating – and we’re over the moon to be working with them.
In case you’re unfamiliar with Genomics England’s story, it was set up in 2012 to conduct a landmark project to sequence 100,000 whole genomes. This unprecedented goal was achieved two years ago, making the UK the first country to do so.
The project has since kick-started the development of a local genomics industry and harnessed a new generation of genomic technology – reinforcing the UK as the leading country for genetic research.
Genomics England has now transitioned and struck partnerships with some of the world’s leading pharmaceutical companies and scientists, enabling them to conduct research to deliver a new generation of medications and treatments, based on a patient’s genome. This is a revolutionary new approach to personalised and individualised health care which will enable predictive and preventative care, medications and treatments.
They’re also making inroads towards another radical goal – for the UK to become the first country in the world to introduce whole genome sequencing as part of routine health care. Ultimately Genomics England will work with the National Health Service to deliver and improve genomic testing to assist doctors diagnose, treat and prevent illnesses like cancer and rare diseases.
As we currently battle with the pandemic, it’s wonderful to be involved with Genomics England’s ground-breaking journey to improve the mental and physical wellbeing of the UK population and millions more worldwide.
Watch this space for our updates about media coverage over the coming months.